Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Noxopharm Ltd V.NOX


Primary Symbol: NOXOF

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.


OTCPK:NOXOF - Post by User

Post by loonietuneson Jul 06, 2015 8:48am
122 Views
Post# 23894080

Test results are out

Test results are outNiogold recovers average 88.3% Au at Marban 2015-07-06 08:27 ET - News Release Mr. Michael Iverson reports NIOGOLD REPORTS PRELIMINARY LEACH TEST RESULTS AT MARBAN Niogold Mining Corp. has released the results of 50 bottle-roll leach tests on representative mineralized core samples from the Marban deposit, located on Niogold's 100-per-cent-owned Marban block property in the Malartic gold camp, Abitibi district, Quebec. Samples were ground to an average of 65 microns and leached for 36 hours, similar to leaching conditions at the nearby Canadian Malartic mine. Results indicate an average recovery of 88.3% over a grade range of 0.22 to 4.40 g/t Au (avg. 1.39 g/t Au) with average cyanide (NaCN) consumption of 0.17 kg per tonne. Results are summarized below for four sample populations: Number ofGrade Range Avg. Grade Avg. P80NaCN Consumption Recovery RangeAverage Recovery Samples (calc. g/t Au)(calc. g/t Au)microns kg/t Au % Au % 8 0.22 - 0.50 0.37 62.3 0.13 83.3 - 93.8 89.5 23 0.51 - 1.50 0.90 65.8 0.18 78.6 - 96.1 89.7 14 1.51 - 2.50 2.07 64.0 0.19 71.9 - 98.1 85.4 5 2.51 - 4.40 3.34 66.4 0.16 81.3 - 98.0 88.1 Average 0.22 - 4.40 1.39 64.8 0.17 - 88.3 Four samples in the 1.20-2.30 g/t Au range gave poor results (less than 78% recovery), possibly due to the presence of coarser gold grains. Check analyses will be performed on these samples to confirm results. If these four samples are excluded from the set, the average recovery is 89.5% with a range of 81.3% to 98.0% across the entire sample population. Robert Wares, P. Geo., Niogold's President and CEO, stated: "Leach results from this first run of samples are excellent. Average recovery around the 88-89% mark is comparable to Canadian Malartic ore under similar leach times and cyanide consumption levels. More importantly, the average recoveries at Marban are close throughout the four sample populations, giving a flat grade/recovery curve with no significant drop in lower grade material. This is a very positive feature of the deposit and will be confirmed with additional testing." An additional set of fifty samples will be sent at for leach tests at SGS Mineral Services in order to confirm preliminary test results and improve statistics on the grade/recovery curve. Technical Info, QA/QC and Qualified Persons Metallurgical program design and monitoring are being executed under the supervision of Mr Christian Laroche, P. Eng. and Mr. Yan Ducharme, M.Sc., P.Geo. (OGQ), Niogold's Vice-President Exploration, both Qualified Persons as defined by National Instrument 43-101. Metallurgical testing and analyses were performed at SGS Mineral Services in Lakefield, Ontario. QA/QC program utilized is consistent with NI 43-101 and industry best practice standards. This news release was reviewed and approved by Mr. Laroche and Mr. Ducharme. We seek Safe Harbor. 2015 Canjex Publishing Ltd. All rights reserved
<< Previous
Bullboard Posts
Next >>